Shares of Intec Pharma Ltd. (NASDAQ:NTEC) have received an average recommendation of “Buy” from the six ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $11.00.
Several analysts recently issued reports on the stock. Oppenheimer boosted their target price on shares of Intec Pharma from $10.00 to $15.00 and gave the company an “outperform” rating in a research report on Thursday, September 21st. Roth Capital set a $10.00 target price on shares of Intec Pharma and gave the company a “buy” rating in a research report on Thursday, August 10th. Zacks Investment Research upgraded shares of Intec Pharma from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd. CIBC restated an “outperform” rating and set a $15.00 target price (up from $10.00) on shares of Intec Pharma in a research report on Thursday, September 21st. Finally, Maxim Group set a $8.00 target price on shares of Intec Pharma and gave the company a “buy” rating in a research report on Friday, November 17th.
Shares of Intec Pharma (NASDAQ NTEC) opened at $5.55 on Tuesday. Intec Pharma has a 12-month low of $4.20 and a 12-month high of $9.80.
Intec Pharma Company Profile
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.